Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Omipalisib | 3 | 72 | 0.001 | 2990.5 | 3523.0 | 586.9 | -3.0 | 0.877 | 0.849 | 2.586 | BT20 GSK458 0 3 |
| BT-20 | KIN001-244 | 3 | 72 | 0.001 | 3545.3 | 3578.0 | 586.9 | -3.0 | 0.993 | 0.991 | 2.608 | BT20 KIN001-244 0 3 |
| BT-20 | XL147 | 1 | 72 | 0.001 | 5542.8 | 6311.0 | 1443.3 | -3.0 | 0.882 | 0.878 | 2.128 | BT20 XL147 0 1 |
| BT-20 | Everolimus | 2 | 72 | 0.001 | 1803.0 | 3213.5 | 1018.6 | -3.0 | 0.411 | 0.561 | 1.658 | BT20 Everolimus 0 2 |
| BT-20 | TGX221 | 1 | 72 | 0.001 | 5503.5 | 5723.8 | 1443.3 | -3.0 | 0.961 | 0.962 | 1.988 | BT20 TGX221 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 0.001 | 5598.0 | 6240.0 | 1443.3 | -3.0 | 0.900 | 0.897 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | GDC-0980 | 2 | 72 | 0.001 | 3333.5 | 3217.8 | 1018.6 | -3.0 | 1.040 | 1.040 | 1.659 | BT20 GDC0980 0 2 |
| BT-20 | TGX221 | 3 | 72 | 0.001 | 2926.0 | 3248.8 | 586.9 | -3.0 | 0.917 | 0.901 | 2.469 | BT20 TGX221 0 3 |
| BT-20 | ZSTK474 | 1 | 72 | 0.001 | 5978.0 | 5537.8 | 1443.3 | -3.0 | 1.080 | 1.080 | 1.940 | BT20 ZSTK474 0 1 |
| BT-20 | Omipalisib | 2 | 72 | 0.001 | 3128.0 | 3349.0 | 1018.6 | -3.0 | 0.922 | 0.934 | 1.717 | BT20 GSK458 0 2 |
| BT-20 | KIN001-244 | 1 | 72 | 0.001 | 6021.5 | 6295.0 | 1443.3 | -3.0 | 0.959 | 0.957 | 2.125 | BT20 KIN001-244 0 1 |
| BT-20 | PI103 | 1 | 72 | 0.001 | 5370.5 | 5476.0 | 1443.3 | -3.0 | 0.980 | 0.981 | 1.924 | BT20 PI103 0 1 |
| BT-20 | AS605240 | 1 | 72 | 0.001 | 5834.8 | 6371.0 | 1443.3 | -3.0 | 0.920 | 0.916 | 2.142 | BT20 AS605240 0 1 |
| BT-20 | Everolimus | 1 | 72 | 0.001 | 3773.0 | 5781.0 | 1443.3 | -3.0 | 0.616 | 0.653 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | Buparlisib | 1 | 72 | 0.001 | 5907.8 | 6321.8 | 1443.3 | -3.0 | 0.937 | 0.935 | 2.131 | BT20 BKM120 0 1 |
| BT-20 | Trametinib | 1 | 72 | 0.001 | 5603.8 | 5837.3 | 1443.3 | -3.0 | 0.960 | 0.960 | 2.016 | BT20 Trametinib 0 1 |
| BT-20 | AZD8055 | 1 | 72 | 0.001 | 5501.0 | 5941.5 | 1443.3 | -3.0 | 0.926 | 0.926 | 2.041 | BT20 AZD8055 0 1 |
| BT-20 | AZD-6482 | 2 | 72 | 0.001 | 2737.3 | 3186.5 | 1018.6 | -3.0 | 0.824 | 0.859 | 1.645 | BT20 AZD6482 0 2 |
| BT-20 | Omipalisib | 1 | 72 | 0.001 | 5515.0 | 6095.3 | 1443.3 | -3.0 | 0.906 | 0.905 | 2.078 | BT20 GSK458 0 1 |
| BT-20 | GDC-0980 | 1 | 72 | 0.001 | 5617.0 | 5778.5 | 1443.3 | -3.0 | 0.972 | 0.972 | 2.001 | BT20 GDC0980 0 1 |
| BT-20 | AZD-6482 | 1 | 72 | 0.001 | 5532.3 | 5948.8 | 1443.3 | -3.0 | 0.930 | 0.930 | 2.043 | BT20 AZD6482 0 1 |
| BT-20 | Pictilisib | 1 | 72 | 0.001 | 5849.5 | 6125.0 | 1443.3 | -3.0 | 0.956 | 0.955 | 2.085 | BT20 GDC0941 0 1 |
| BT-20 | Torin2 | 1 | 72 | 0.001 | 5188.5 | 5846.0 | 1443.3 | -3.0 | 0.885 | 0.888 | 2.018 | BT20 Torin2 0 1 |
| BT-549 | AZD8055 | 1 | 72 | 0.001 | 5177.5 | 5342.3 | 1554.9 | -3.0 | 0.965 | 0.969 | 1.781 | BT549 AZD8055 0 1 72 |
| BT-549 | AZD-6482 | 1 | 72 | 0.001 | 5306.0 | 5406.8 | 1554.9 | -3.0 | 0.979 | 0.981 | 1.798 | BT549 AZD6482 0 1 72 |